spacer
home > ebr > autumn 2017 > enhanced effects
PUBLICATIONS
European Biopharmaceutical Review

Enhanced Effects

Cellular therapies – such as treatment with mesenchymal stem cells (MSCs) or, recently, with genetically adapted T-autologous (Ta) cells – are coming of age and have exhibited their efficacy for selected indications in numerous preclinical trials. Many have received first approvals or are likely to in the near future. MSCs have been approved for selected indications in Canada as well as New Zealand, and at least one chimeric antigen receptor (CAR) T-cell product has gained a unanimous positive review by the FDA advisory committee.

The cross-section of medical devices and cellular therapies has been explored and utilised for some time; for example, cells have been embedded in collagenous foams to secure their location, or catheters have been employed to facilitate targeted delivery of cells.

For biologics and small molecules, this cross-section is perhaps not as clearly visible, yet it has transpired that combinations may yield massive improvements, as demonstrated in preclinical studies. Hence, this appears to be an opportunity worthy of exploration due to its benefits as well as its practical, quality and regulatory implications.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Christian van den Bos founded Mares Ltd in 2007 to accelerate the development of regenerative medicinal products and currently serves as its Managing Director. He underwent postdoctoral training at Cold Spring Harbor Laboratories, US, and earned a PhD at the University of Münster, Germany, as well as an MSc at the University of Oxford, UK.
spacer
Dr Christian van den Bos
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Digital Health and Wearables

• Datwyler uses strategic partnerships to develop new solutions in the fields of wearables and digital health. • The company’s health care offering is always designed towards improving the comfort of patients during treatment. • The product portfolio and innovative healthcare solutions will be presented at several important trade fairs of the medical sector.
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 
Industry Events

Pre-Filled Syringes & Injectable Drug Devices Europe

16-17 January 2019, Copthorne Tara Hotel, London

SMi is proud to present their 11th annual European conference and exhibition, within the Pre-Filled Syringes series: Pre-Filled Syringes & Injectable Drug Devices Europe. The event will take place on the 16th-17th of January 2019, in London.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement